Abstract:Mitochondria were increased in acquired GEM‐resistant pancreatic cancer cell lines, which induced oxidative phosphorylation (OXPHOS) and upregulation of BCL2 and BCL‐xL anti‐apoptotic proteins. As a result of OXPHOS, the AMP/ATP ratio and AMP‐activated protein kinase (AMPK) activity were decreased, which activated the heat shock factor 1 (HSF1)–heat shock protein (HSP) pathway to promote environmental stress tolerance. Pancreatic ductal adenocarcinoma has a particularly poor prognosis as it is often detected at an advanced stage and acquires resistance to chemotherapy early during its course. Stress adaptations by mitochondria, such as metabolic plasticity and regulation of apoptosis, promote cancer cell survival; however, the relationship between mitochondrial dynamics and chemoresistance in pancreatic ductal adenocarcinoma remains unclear. We here established human pancreatic cancer cell lines resistant to gemcitabine from MIA PaCa‐2 and Panc1 cells. We compared the cells before and after the acquisition of gemcitabine resistance to investigate the mitochondrial dynamics and protein expression that contribute to this resistance. The mitochondrial number increased in gemcitabine‐resistant cells after resistance acquisition, accompanied by a decrease in mitochondrial fission 1 protein, which induces peripheral mitosis, leading to mitophagy. An increase in the number of mitochondria promoted oxidative phosphorylation and increased anti‐apoptotic protein expression. Additionally, enhanced oxidative phosphorylation decreased the AMP/ATP ratio and suppressed AMPK activity, resulting in the activation of the HSF1–heat shock protein pathway, which is required for environmental stress tolerance. Synergistic effects observed with BCL2 family or HSF1 inhibition in combination with gemcitabine suggested that the upregulated expression of apoptosis‐related proteins caused by the mitochondrial increase may contribute to gemcitabine resistance. The combination of gemcitabine with BCL2 or HSF1 inhibitors may represent a new therapeutic strategy for the treatment of acquired gemcitabine resistance in pancreatic ductal adenocarcinoma.

The molecular biological mechanism of acquired resistance of pancreatic cancer cells to 5-FU and gemcitabine

Possible Mechanisms of Acquired Resistance to 5-FU in Human Colon Cancer

CXCL5 knockdown attenuated gemcitabine resistance of pancreatic cancer through regulation of cancer cells and tumour stroma.

Effect of Gemcitabine on Proliferation, Apoptosis and Polo-Like Kinase-1 Expression of Pancreatic Cancer Cell Line AsPC-1

Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell lines

Targeting Mitochondrial Transcription Factor A Sensitizes Pancreatic Cancer Cell to Gemcitabine.

Survivin is Involved in Drug Resistance of Pancreatic Cancer PaTu8988 Cells to Gemcitabine

Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models.

Gemcitabine Resistance is Associated with Epithelial-Mesenchymal Transition and Induction of HIF-1α in Pancreatic Cancer Cells.

Study of the survivin expression in pancreatic carcinoma cell line PANC-1 induced by gemcitabine

Data from Synergistic Antitumor Activity of Gemcitabine and ABT-737 <i>In Vitro and In Vivo</i> through Disrupting the Interaction of USP9X and Mcl-1

Hypoxia increase the resistance of human pancreatic cancer cells to gemcitabine chemotherapy

Stem cell factor modulates HIF‐1α levels and diminishes 5‐FU sensitivity in 5‐FU resistant pancreatic cells by altering the anabolic glucose metabolism

Gene Microarrays in Detecting Molecular Mechanisms of Gemcitabine-Mediated Apoptosis on Human Pancr- Eatic Carcinoma Cells Panc-1

microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer

Expression of XIAP in Pancreatic Carcinoma Cell Line BxPC-3 Induced by Gemcitabine

Mechanisms of spermidine/spermine N1-acetyltransferase 2 in the chemoresistance of pancreatic cancer to gemcitabine

EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer

OXCT1 Enhances Gemcitabine Resistance Through NF-B Pathway in Pancreatic Ductal Adenocarcinoma

USP9X Inhibition Improves Gemcitabine Sensitivity in Pancreatic Cancer by Inhibiting Autophagy